Kessler Topaz Meltzer & Check, LLP Reminds Investors of Neumora Therapeutics, Inc. Securities Fraud Lawsuit Filed Against NMRA

CLASS ACTION LAWSUIT REMINDER: NMRA, KESSLER, TOPAZ, MELTZER CHECK LLP REMINDS NEUMORA THERAPEUTICS INC. INVESTORS OF UPCOMING DEADLINE IN SHAREHOLDERS' LAWSUIT

New York, NY - NMRA, KESSLER, TOPAZ, MELTZER CHECK LLP reminds investors of Neumora Therapeutics Inc. that the deadline to file a motion to serve as lead plaintiff in the securities class action lawsuit filed on behalf of investors who purchased or acquired Neumora Therapeutics Inc. securities between April 13, 2022 and October 14, 2022, inclusive, is approaching.

The lawsuit, filed in the United States District Court for the Southern District of New York, alleges that Neumora Therapeutics Inc. and certain of its executives made false and misleading statements to the public, violating federal securities laws. Specifically, the lawsuit claims that the defendants made false and misleading statements about the company's business, financial condition, and prospects, causing the company's stock price to artificially inflate.

Investors who purchased or acquired Neumora Therapeutics Inc. securities between April 13, 2022 and October 14, 2022, inclusive, are encouraged to contact NMRA, KESSLER, TOPAZ, MELTZER CHECK LLP to discuss their legal rights and options. The deadline to file a motion to serve as lead plaintiff is [insert date].

If you have any questions or concerns, please contact NMRA, KESSLER, TOPAZ, MELTZER CHECK LLP at [insert contact information]. You can also visit our website at [insert website] for more information.